Cascade Biotechnology INC.Cascade Biotechnology INC.
  • Home
  • Announcements
  • Complement Therapeutics General Overview
  • Complement Therapeutics Disease Indications
  • Pipeline
  • Diabetic Nephropathy (DN) and lupus nephritis (LN)
  • Alzheimer's disease
  • Schizophrenia
  • Multiple Sclerosis-Autoimmune
  • Neuromyelitis Optica-Autoimmune
  • Myasthenia Gravis-Autoimmune
  • Amyotrophic Lateral Sclerosis (ALS) Autoimmune
  • Age-Related Macular Degeneration
  • Paroxysmal Nocturnal Hemoglobinuria
  • Cardiac and Myocardial Ischemia
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Technology
  • Staff Publications
  • Funding
  • Scientific Advisory Board (SAB)
  • Management
  • Images  
  • Complement Depletion and Disease Models
  • Human C3-1496 Potential Immunogenicity
  • C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
  • sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
  • sC3 Depletes Complement More Potently than CVF
  • sC3 is More Stable in Serum
  • sC3 Resists Degradation
  • sC3 Gene Therapy Strategy
  • sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
  • sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
  • sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
  • sC3 Cascade Intellectual Property
  • Gallery
  • What's Hot in Complement 2020-2023
     
    Cascade Biotechnology INC.Cascade Biotechnology INC.
      • Home
      • Announcements
      • Complement Therapeutics General Overview
      • Complement Therapeutics Disease Indications
      • Pipeline
      • Diabetic Nephropathy (DN) and lupus nephritis (LN)
      • Alzheimer's disease
      • Schizophrenia
      • Multiple Sclerosis-Autoimmune
      • Neuromyelitis Optica-Autoimmune
      • Myasthenia Gravis-Autoimmune
      • Amyotrophic Lateral Sclerosis (ALS) Autoimmune
      • Age-Related Macular Degeneration
      • Paroxysmal Nocturnal Hemoglobinuria
      • Cardiac and Myocardial Ischemia
      • Atypical Hemolytic Uremic Syndrome (aHUS)
      • Technology
      • Staff Publications
      • Funding
      • Scientific Advisory Board (SAB)
      • Management
      • Images  
      • Complement Depletion and Disease Models
      • Human C3-1496 Potential Immunogenicity
      • C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
      • sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
      • sC3 Depletes Complement More Potently than CVF
      • sC3 is More Stable in Serum
      • sC3 Resists Degradation
      • sC3 Gene Therapy Strategy
      • sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
      • sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
      • sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
      • sC3 Cascade Intellectual Property
      • Gallery
      • What's Hot in Complement 2020-2023
      1. Home
      2. Gallery

      See Full Gallery
      •  
      •  
      •  
      • Home
      • Announcements
      • Complement Therapeutics General Overview
      • Complement Therapeutics Disease Indications
      • Pipeline
      • Diabetic Nephropathy (DN) and lupus nephritis (LN)
      • Alzheimer's disease
      • Schizophrenia
      • Multiple Sclerosis-Autoimmune
      • Neuromyelitis Optica-Autoimmune
      • Myasthenia Gravis-Autoimmune
      • Amyotrophic Lateral Sclerosis (ALS) Autoimmune
      • Age-Related Macular Degeneration
      • Paroxysmal Nocturnal Hemoglobinuria
      • Cardiac and Myocardial Ischemia
      • Atypical Hemolytic Uremic Syndrome (aHUS)
      • Technology
      • Staff Publications
      • Funding
      • Scientific Advisory Board (SAB)
      • Management
      • Complement Depletion and Disease Models
      • Human C3-1496 Potential Immunogenicity
      • C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
      • sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
      • sC3 Depletes Complement More Potently than CVF
      • sC3 is More Stable in Serum
      • sC3 Resists Degradation
      • sC3 Gene Therapy Strategy
      • sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
      • sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
      • sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
      • sC3 Cascade Intellectual Property
      • Gallery
      • What's Hot in Complement 2020-2023
      Copyright © 2025 All rights reserved - Cascade Biotechnology INC.
      •  +1-609-610-3935
      •   edholland@cenoxsys.com
      •   1 Deer Park Dr., Suite D5, Princeton Corporate Plaza, Monmouth Junction, NJ 08852
      • Google Maps
      • Waze
      • Moovit
      • Moovit
      •  
      •  
      •